Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report

By A. Rush, Madhukar H. Trivedi, S. Wisniewski, A. Nierenberg, J. Stewart, D. Warden, G. Niederehe, M. Thase, Philip W. Lavori, B. Lebowitz and 6 more. 2006

3,189 citations recorded by the source corpus.

Subfields: Applied Psychology, Clinical Psychology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/02c2018346cad0f22827d2f615f42c278424ee90

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Psychology

In Pharmacology

Citations in the corpus

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders (2015, background): “(Rush et al., 2006) showed that after four successive trials of antidepressants a cumulative remission rate of 67% was reached, though it may require 2–3 antidepressant trials before complete remission is reached.”
Psychedelics Promote Structural and Functional Neural Plasticity (2018, background): “…antidepressant drugs, and those who do will usually require at least 2–4 weeks of treatment before they experience any beneficial effects 3170 Cell Reports 23, 3170–3182, June 12, 2018 ª 2018 The Author( This is an open access article under the CC BY-NC-ND license (http:// (Rush et al., 2006).”
Polygenic risk scores: from research tools to clinical instruments (2020, background): “Only one third of patients respond to the first anti-depressant prescribed [74], so a polygenic predictor might be useful to guide treatment; even a modest increase in the proportion of patients responding could have a substantial impact on the effectiveness and time to recovery.”
The diagnosis of mental disorders: the problem of reification. (2010, background): “…as the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D), have found that treatments efficacious for pure DSM-IV disorders, such as Major Depression, are less so in the large fraction of patients who have additional symptoms such as anxiety (Howland et al. 2009, Rush et al. 2006).”
Neuroinflammation and depression: A review (2020, background): “, 2006) and that the remission rate increases up to 60% after two different antidepressant trials (Rush et al., 2006), it can be deduced that the neurobiological mechanisms of depression cannot be solely explained as the consequence of these three mechanisms.”
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. (2022, background): “Any severe adverse event 7 (9) 5 (7) 1 (1)”
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders (2008, background): “Although most patients with mood disorders receive some benefit from available treatment”